Refine by
Immune Antibody Articles & Analysis
41 news found
Recent advances in the architecture and scale of AI are leading us from the era of narrowly focused AI (e.g. text auto-complete, immune epitope prediction in a protein sequence, antibody domain detection) to broader models with applications across domains from sales and marketing to medical diagnostics. ...
The results were published in the article “A Personal COVID-19 Dendritic Cell Vaccine Made at Point-of-Care: Feasibility, Safety, and Antigen-Specific Cellular Immune Responses” in the journal Human Vaccines & Immunotherapeutics. ...
As communicated on December 7, 2021, immunological analyses after 5-months showed that the treatment with Diamyd® induced a clear GAD-specific immune response both in term of antibodies and cell-based reactions in individuals diagnosed with LADA . ...
The immunological analyses showed a similar response to the treatment as has been shown in previous trials in individuals with recent-onset type 1 diabetes, with a clear GAD-specific immune response evident in both circulating antibodies and cell-based reactions. ...
Usually a certain protein in the food is not welcomed by the patient’s body, generating a severe immune reaction. The body analyzes that protein as a foreign particle or antigen and attacks it with the help of immune cells. Allergic reactions are mediated by IgE type immune response. The IgE antibodies are formed on the ...
The paper entitled “A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity” shows that Ziphius’ multi-antigenic self-amplifying RNA COVID-19 vaccine candidate induces a potent humoral and cellular immune ...
As a global leading supplier of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently launches a series of NiV recombinant antigen and antibody pairs. ...
The Company will present a scientific poster on the therapeutic potential of anti-LAIR1 antibodies at the Society for Immunotherapy of Cancer (SITC) Tumor Immune Microenvironment: A Holistic Approach Workshop on April 21st in San Diego, CA. ...
The GlyMab™ technology is part of Scancell’s antibody portfolio, joining AvidiMab® , a technology that can be applied to all antibodies (regardless of the technology used to generate them), enhancing their potency and ability to directly kill tumour cells. ...
ByScancell
The Phase 1 trial is testing Scancell’s two clinical candidates, SCOV1 and SCOV2 (COVIDITY), which in preclinical models have induced high titre antibodies and potent T cells against both the S and N antigens, including responses that cross-react with the Delta and Omicron variants. ...
ByScancell
“Omicron exposes limitations of antiviral monoclonal antibody therapy in COVID-19 – a clear opportunity for host-cell directed drugs like zapnometinib. ...
Over the past decade, immunotherapy has become one of the mainstays of cancer treatment, thanks in large part to monoclonal antibodies targeting the immune checkpoint protein PD-1 or its major ligand PD-L1 (mAbs). Due to abnormal immune surveillance mediated by immune checkpoints, tumor cells develop immune ...
(Prellis), a Bay Area biotherapeutics company, announced today that it has entered into a collaboration and license option agreement with Sanofi S.A. focused on the discovery of antibodies with Prellis’ first-in-class external human immune system (EXIS). The collaboration leverages Prellis’ ability to engineer fully-human lymph node organoids ...
PHILADELPHIA, March 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that five abstracts have been selected for poster or symposium presentations at the American Association for ...
(Prellis), a Bay Area biotechnology company, announced today that it has entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing Prellis Biologics’ first-in-class externalized human immune system (EXIS) based on human lymph node organoids (LNO). The collaboration leverages Prellis’ EXIS platform that can ...
“In deploying our cutting-edge ADC technology platform together with Genmab’s robust antibody development capabilities, Synaffix is privileged to once more play an essential role in strengthening a partner’s pipeline with our innovative ADC technologies thereby aiding the transformation of cancer ...
As reported in several recent high-profile publications, Nature Biotechnology and Nature Immunology, the SNAPvaxTM platform uses self-assembly to co-deliver multiple antigens and immunomodulators in nanoparticles of precise, programmable size and composition, thereby enabling immunotherapy product candidates with tighter control over immune responses. The SNAPvaxTM platform can ...
"Due to the potential for anti-vector immunity after primary Ervebo vaccination, boosting with the same vaccine several years later may not be possible. ...
"DNA medicines" are composed of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body. INOVIO's vaccine and immunotherapy candidates deliver optimized plasmids directly into cells intramuscularly or intradermally using INOVIO's ...
Immune Biosolutions is pleased to announce the start of Phase I clinical trial for its immunotherapy (IBIO123) treatment, whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants. ...